AU583801B2 - Method and materials for sensitizing neoplastic tissue to radiation - Google Patents

Method and materials for sensitizing neoplastic tissue to radiation

Info

Publication number
AU583801B2
AU583801B2 AU36107/84A AU3610784A AU583801B2 AU 583801 B2 AU583801 B2 AU 583801B2 AU 36107/84 A AU36107/84 A AU 36107/84A AU 3610784 A AU3610784 A AU 3610784A AU 583801 B2 AU583801 B2 AU 583801B2
Authority
AU
Australia
Prior art keywords
chloro
deoxycytidine
radiation
deamination
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36107/84A
Other languages
English (en)
Other versions
AU3610784A (en
Inventor
Sheldon B. Greer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3610784A publication Critical patent/AU3610784A/en
Application granted granted Critical
Publication of AU583801B2 publication Critical patent/AU583801B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU36107/84A 1983-10-26 1984-10-26 Method and materials for sensitizing neoplastic tissue to radiation Ceased AU583801B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54569383A 1983-10-26 1983-10-26
US545693 1983-10-26

Publications (2)

Publication Number Publication Date
AU3610784A AU3610784A (en) 1985-05-22
AU583801B2 true AU583801B2 (en) 1989-05-11

Family

ID=24177186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36107/84A Ceased AU583801B2 (en) 1983-10-26 1984-10-26 Method and materials for sensitizing neoplastic tissue to radiation

Country Status (5)

Country Link
EP (1) EP0160079B1 (enExample)
JP (1) JPS61500224A (enExample)
AU (1) AU583801B2 (enExample)
DE (1) DE3481172D1 (enExample)
WO (1) WO1985001871A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815448A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
US4815447A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
JP2785025B2 (ja) 1985-03-19 1998-08-13 ランデル・エル・ミルズ 診断と選択的組織壊死を与える装置
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ES2273672T3 (es) * 1999-03-01 2007-05-16 Halogenetics, Inc. Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas.
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2416781B1 (en) 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
CS184526B1 (en) * 1976-02-19 1978-08-31 Dieter Cech 2'-halogen-2'-deoxy-5-fluoruridine,3',5-di-o-benzoyl-derivatives and process for preparing thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases

Also Published As

Publication number Publication date
JPH0586376B2 (enExample) 1993-12-10
EP0160079A4 (en) 1986-05-14
WO1985001871A1 (en) 1985-05-09
DE3481172D1 (de) 1990-03-08
EP0160079B1 (en) 1990-01-31
JPS61500224A (ja) 1986-02-06
AU3610784A (en) 1985-05-22
EP0160079A1 (en) 1985-11-06

Similar Documents

Publication Publication Date Title
US4894364A (en) Method and materials for sensitizing neoplastic tissue to radiation
EP1491201B1 (en) Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides
EP0160079B1 (en) Method and materials for sensitizing neoplastic tissue to radiation
US20030125298A1 (en) Cancer therapy comprising deaminase enzyme inhibitors
EP1100512B1 (en) Use of thioarabinofuranosyl compounds
US4434788A (en) Enhancer of anti-tumor effect
Huang et al. Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics
US4432348A (en) Enhancer of anti-tumor effect
JPS637164B2 (enExample)
Fujii et al. Antitumor activity of BOF‐A2, a new 5‐fluorouracil derivative
Arnér On the phosphorylation of 2-chlorodeoxy-adenosine (CdA) and its correlation with clinical response in leukemia treatment
Rich Irradiation plus 5-fluorouracil: cellular mechanisms of action and treatment schedules
Martin et al. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue
JP2688057B2 (ja) 抗腺がん剤
CA1269658A (en) Method and materials for sensitizing neoplastic tissue to radiation
EP3563856B1 (en) Pharmaceutical composition comprising capecitabine, gimeracil, and oteracil for treating cancer and use thereof
Lin et al. Antitumor activity of the 3′-chloroethylnitrosourea analog of thymidine and the prevention by co-administered thymidine of lethality but not of anticancer activity
Fujimoto et al. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride
US5496810A (en) Pyrimidine deoxyribonucleoside potentiation of combination therapy based on 5-fluorouracil and interferon
JPS6345372B2 (enExample)
Miles et al. Biochemical and biophysical approaches to improving the anticancer effectiveness of ara-adenine
Shirasaka et al. 23 Preclinical and Clinical Practice of S
Boothman et al. Use of 5-Fluorodeoxycytidine and Tetrahydrouridine to Exploit High Levels of Deoxycytidylate Deaminase in Tumors to Achieve DNA-and Target-directed Therapies1
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan
Capizzi et al. DOSE‐RELATED PHARMACOLOGIC EFFECTS OF HIGH DOSE ARA‐C AND ITS USE IN COMBINATION WITH ASPARAGINASE FOR THE TREATMENT OF PATIENTS WITH ACUTE NON‐LYHPHOCYTIC LEUKEMIA

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired